Skip to main content
News Icon

COVIMMUNE being funded

A new consortium COVIMMUNE under the direction of Prof. Eicke Latz, speaker of the cluster of Excellence ImmunoSensation2 is being funded with around 2 Million Euros by the Federal Ministry of Education and Research (BMBF). The project "Understanding divergent host reactions to SARS-CoV-2 infections by precision immunology" (COVIMMUNE) brings together clinical researchers at the University Hospital Bonn who are involved in COVID-19 patient care with basic scientists with immunological expertise from the University of Bonn.

"We want to find out the connection between the mechanisms of the immune response to the SARS-CoV-2 infection and the clinical course of the disease," says Prof. Dr. Eicke Latz. Around two dozen personalities from disciplines such as virology, internal medicine, intensive care medicine, pulmonology, neurology, immunology, blood coagulation, bioinformatics and systems biology are involved. Together they want to contribute to a better understanding of the different course of the disease in SARS-CoV-2 infections. Prof. Natalio Garbi heads the sub-project of the consortium on adaptive immunity. He says: "We want to test whether the interaction of the innate and the acquired (adaptive) immune response is the key to eliminating the infection and developing long-term immunity without long-term health consequences."

The aim is to find out how the SARS-CoV-2 virus can trigger a misdirected immune response and what role this plays in severe COVID-19 disease courses. Furthermore, a clinical study will investigate which factors cause long-term damage to the lungs and the nervous system. Prof. Dr. Michael Heneka, whose sub-project in the consortium is looking at the secondary diseases of the lungs and the central nervous system caused by COVID-19, says: "It is not yet well understood how infection with the SARS-CoV-2 virus can trigger such secondary diseases. We want to examine these relationships in a clinical study in order to be able to offer better treatment options."


Contact

Prof. Dr. Eicke Latz

Institute of Innate Immunity, University of Bonn

Phone: 0228/287-51223

E-Mail: eicke.latz@uni-bonn.de

Related news

News Icon

News categories: Publication

B cells maintain antigen presentation in the splenic marginal zone

A team of international researchers, including ImmunoSensation³ members Prof. Niels Lemmermann and Prof. Andreas Schlitzer, shows that B cells support antiviral CD8⁺ T-cell responses beyond antibody production. In a murine CMV model, B-cell deficiency weakened virus-specific CD8⁺ T-cell responses. Mechanistically, B-cell-derived lymphotoxin β maintained CD169⁺ macrophages and Langerin⁺ cDC1 cells in the splenic marginal zone, enabling efficient T-cell priming. The study was published in Cellular & Molecular Immunology.
Full publication
Zwei Personen: Links Prof. Pröpstl und rechts Prof. Boztug

News categories: Honors & Funding

University of Bonn and University Hospital Bonn strengthen early-career clinical scientists

The Faculty of Medicine at the University of Bonn and the University Hospital Bonn (UKB) are jointly launching the EKFS doctoral program IMMUNE PILOT, which introduces medical students to clinical-scientific research at an early stage. The structured program is positioned at the interface of immunology, neuroscience, and genetics and is aimed at students with a strong interest in research who aspire to pursue a career as clinician scientists. The program is funded by the Else Kröner-Fresenius Foundation (EKFS).
View entry
PrepAIred

News categories: Honors & Funding

Precise active ingredients against pancreatic cancer

Pancreatic cancer remains one of the deadliest forms of cancer. At the German Cancer Congress 2026, German Cancer Aid is now presenting three large-scale projects that it is funding as part of its “German Alliance for Pancreatic Cancer” funding priority. In the funded project PrepAIred, Bonn researchers , in cooperation with the University of North Carolina (USA), want to use AI-based protein design to specifically combat pancreatic cancer. German Cancer Aid is funding the project with a total of 1.99 million euros over a period of four years.
View entry

Back to the news overview